Cargando…
Calcipotriol/Betamethasone Dipropionate Cutaneous Foam Treatment for Psoriasis in Patients With BSA 5–15% and PGA ≥ 3: Post-Hoc Analysis From Three Randomized Controlled Trials
INTRODUCTION: Psoriasis is a chronic, inflammatory disease, which ranges in severity from mild to severe. Although topical therapies are frequently used to treat mild disease, they are not routinely used to treat patients with moderate-to-severe disease who have a larger proportion of their body sur...
Autores principales: | Iversen, Lars, Kurvits, Merle, Snel-Prentø, Anja Marieke, Menter, Alan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7477061/ https://www.ncbi.nlm.nih.gov/pubmed/32785881 http://dx.doi.org/10.1007/s13555-020-00419-2 |
Ejemplares similares
-
Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam For Scalp Psoriasis
por: Anderko, Marian, et al.
Publicado: (2019) -
Calcipotriol/betamethasone dipropionate in the treatment of psoriasis vulgaris
por: Vakirlis, Efstratios, et al.
Publicado: (2008) -
Efficacy and Safety of Different Formulations of Calcipotriol/Betamethasone Dipropionate in Psoriasis: Gel, Foam, and Ointment
por: Rudnicka, Lidia, et al.
Publicado: (2021) -
Editorial: fixed‐dose combination calcipotriol/betamethasone dipropionate foam in the treatment of patients with psoriasis
por: Lebwohl, M., et al.
Publicado: (2021) -
Calcipotriol/betamethasone dipropionate aerosol foam for the treatment of psoriasis vulgaris: case series and review of the literature
por: Pinter, Andreas, et al.
Publicado: (2018)